This article was originally published in The Gray Sheet
Business-to-business life sciences e-commerce firm completes $1.3 bil. acquisition of medical device Web-based auction company Promedix, Chemdex says Feb. 11. Chemdex will exchange an estimated 12 mil. shares of its common stock for all outstanding Promedix shares, options and warrants under the purchase transaction. Promedix spins off specialty medical product distribution business, which is not part of the deal. Separately, Chemdex finalizes purchase of all shares, options and warrants of privately-held SpecialtyMD.com in exchange for 1.25 mil. shares of Chemdex common stock. At Chemdex' Feb. 10 closing value of 105-3/8, the transaction is valued at approximately $132 mil. SpecialtyMD.com offers clinical and product content to clinicians and purchasing professionals
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.